Kutatási jelek – Signal Engine

New Osteosarcoma Trial at UH Rainbow Attracts National Attention — Osteosarcoma
Update on Merkel Cell Carcinoma — Merkel cell carcinoma
Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer outcomes and toxicity — Anal squamous cell carcinoma
Researchers Show Lorlatinib is Safe, Effective for Patients with High-Risk Neuroblastoma — Neuroblastoma
HemaBlog Issue 1: A Case Study on Acute Myelomonocytic Leukemia (AML-M4) - Mindray — Acute myeloid leukemia
Uveal Melanoma Study — Melanoma
EAU 2023: 15-year Update ProtecT Trial - Part I: Oncology — Prostate cancer
Doxorubicin‑Trabectedin in Leiomyosarcoma — Leiomyosarcoma
Study Uncovers Triple Immunotherapy Combination as Potential Treatment for Pancreatic Cancer | Rutgers Cancer Institute — Pancreatic cancer
Analysis Shows Perioperative Pembrolizumab Efficacy in NSCLC — NSCLC
Frontline Golcadomide/R-CHOP Combo Elicits Antitumor Activity in Aggressive B-Cell Lymphoma — Diffuse large B-cell lymphoma
FDA Approves Epcoritamab for R/R Follicular Lymphoma — Follicular lymphoma
Approvals in 2023 Elevate the CRC, HCC, and Pancreatic Cancer Fields, Paving the Way for More to Come — Hepatocellular carcinoma
Ruti Alon: A New Milestone in the Fight Against Pancreatic Cancer — Pancreatic cancer
Protein discovery could help solve prostate cancer drug resistance — Prostate cancer
Adjuvant nivolumab vs observation in resected Merkel cell carcinoma — Merkel cell carcinoma
Gastrointestinal Stromal Tumor Patients with Molecular Testing Exhibit Superior Survival Compared to Patients without Testing: Results from the Life Raft Group (LRG) Registry. — Gastrointestinal stromal tumor
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON‑Neuroblastoma Trial — Neuroblastoma
Radioimmunotherapy in colorectal cancer treatment: present and future — Colorectal cancer
Trilaciclib May Reduce Single, High-Grade Myelosuppression in ES‑SCLC — SCLC